MTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis

Molecular Cancer Research

Volumn 12, Issue 5, 2014, Pages 703-713

  Acquaviva, Jaime ^a   He, Suqin ^a   Sang, Jim ^a   Smith, Donald L ^a   Sequeira, Manuel ^a   Zhang, Chaohua ^a   Bates, Richard C ^a   Proia, David A ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; 4EGI 1; ADRENERGIC RECEPTOR; ANTINEOPLASTIC AGENT; AZD 8055; CAMPTOTHECIN; CYCLOHEXIMIDE; CYTARABINE; DABIGATRAN; DACTOLISIB; GANETESPIB; GIVINOSTAT; GSK 1059615; HEAT SHOCK TRANSCRIPTION FACTOR 1; INDIRUBIN; MITOXANTRONE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NERATINIB; OBATOCLAX; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PIK 75; RALTITREXED; SEPANTRONIUM BROMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 765; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TYPE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; HEAT SHOCK RESPONSE; IMMUNOASSAY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; METABOLISM; RANDOMIZATION; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HEAT-SHOCK RESPONSE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; PHOSPHATIDYLINOSITOL 3-KINASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIAZOLES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900425382     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0605     Document Type: Article

References (35)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
2. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-55.
3. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010;11:515-28.
4. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-30.
5. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76.
6. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
7. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10: 537-49.
8. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-9.
9. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
10. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-4.
11. Lanneau D, Wettstein G, Bonniaud P, Garrido C. Heat shock proteins: cell protection through protein triage. Sci World J 2010;10:1543-52.
12. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
13. Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010;15:31-8.
14. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62.
15. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 1993;259:1409-10.
16. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998;12:3788-96.
17. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007;21:2172-81.
18. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerfulmultifacetedmodifier of carcinogenesis. Cell 2007;130:1005-18.
19. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012;150: 549-62.
20. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-84.
21. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
22. Chou SD, Prince T, Gong J, Calderwood SK. mTOR is essential for the proteotoxic stress response, HSF1 activation, and heat shock protein synthesis. PloS ONE 2012;7:e39679.
23. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem 1999;68:913-63.
24. Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012;11: 2633-43.
25. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
26. Chatterjee M, Andrulis M, Stuhmer T, Muller E, Hofmann C, Steinbrunn T, et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013;98:1132-41.
27. Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res 2006;66:1783-91.
28. Baler R, Zou J, Voellmy R. Evidence for a role of Hsp70 in the regulation of the heat shock response in mammalian cells. Cell Stress Chaperones 1996;1:33-9.
29. Santagata S, Mendillo ML, Tang YC, Subramanian A, Perley CC, Roche SP, et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 2013;341:1238303.
30. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell-cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-16.
31. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068-77.
32. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013;14: e358-69.
33. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013;39:375-87.
34. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway.Am Soc Clin Oncol Educ Book 2013:395-401.
35. Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good news? Frontiers Oncol 2013;3:108.